Xenon Pharmaceuticals Announces Exciting Investor Webinar
Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a company renowned for its focus on neuroscience, is set to host a compelling investor webinar. This event aims to discuss significant data presentations from the American Epilepsy Society Annual Meeting (AES 2025). The webinar will spotlight groundbreaking long-term data from the ongoing X-TOLE open-label extension study of azetukalner, aimed at treating focal onset seizures (FOS). In addition, the presentation will feature real-world study data exploring the impact of depression and the burden of titration in epilepsy treatment.
Webinar Details to Mark on Your Calendar
Investors and interested parties should mark their calendars for this informative session:
Webinar Topic
Azetukalner and Epilepsy Data Update: AES 2025
Date
Wednesday, December 10, 2025
Time
10:00 AM - 11:00 AM Eastern Time
Registration
To participate, registration is required. Interested attendees can easily register for the webinar through the provided link. Questions may be sent via chat live during the event or submitted in advance via email to investors@xenon-pharma.com.
Exploring Azetukalner: A Promising Therapeutic
At the heart of the webinar is azetukalner, a novel therapy that's showing immense promise for patients suffering from epilepsy. With substantial advancements in treatment options, azetukalner is positioned as a potential game-changer, focusing on Kv7 potassium channel activation, which has significant implications for managing seizure activity and addressing co-morbid conditions like depression.
Company's Growth and Future Plans
Alongside the exciting data, the webinar will offer an update regarding Xenon’s progress toward commercializing azetukalner. With ongoing clinical trials and development phases, the company is on an upward trajectory, exploring additional therapeutic avenues that leverage its innovative discoveries. Xenon also has an early-stage portfolio that focuses on various potassium and sodium channel modulators to aid in developing effective treatments for pain.
Xenon's Commitment to Patients and Innovation
Xenon Pharmaceuticals is committed to changing lives through its research and drugs. The company’s dedication is evident in its ongoing clinical studies and the potential applications of its therapies across various neuropsychiatric conditions. Through the investor webinar, Xenon aims to not only share its latest advancements but also strengthen its connection to the investment community and enhance transparency regarding its product pipelines.
More Information on the Webinar
More details about Xenon's AES 2025 presentations and the overall journey of the company can be discovered in the upcoming webinar. Stay tuned for updates, and do not miss out on this opportunity to engage directly with senior leaders at Xenon Pharmaceuticals.
Frequently Asked Questions
What is the topic of the investor webinar hosted by Xenon?
The webinar will focus on the data presentations related to azetukalner and epilepsy, emphasizing findings from AES 2025.
When will the webinar take place?
The event is scheduled for Wednesday, December 10, 2025, from 10:00 to 11:00 AM Eastern Time.
How can I register for the webinar?
Participants can register through the designated registration link that will be provided in the webinar announcement.
What are the key points about azetukalner?
Azetukalner is a selective Kv7 potassium channel opener currently undergoing Phase 3 clinical trials, aimed at treating epilepsy and other related conditions.
How can I contact Xenon for more information?
For inquiries, you can reach out via email at investors@xenon-pharma.com or contact Colleen Alabiso, Senior Vice President of Corporate Affairs, directly at (617) 671-9238.
